论文部分内容阅读
目的观察肠道微生态制剂在溃疡性结肠炎患者中的应用效果。方法选取2013年3月至2015年3月收治的80例溃疡性结肠炎患者作为研究对象,按随机数字表法分为对照组与观察组,每组40例,对照组接受常规治疗,观察组采用肠道微生态制剂治疗。两组均治疗6个月,评估患者临床症状的改善情况,记录治疗不良反应发生率。结果治疗后,观察组便秘、腹痛、腹胀积分分别降低至(0.8±0.3)、(0.6±0.4)、(0.7±0.5)分,降低幅度明显高于对照组,两组比较差异有统计学意义(P<0.05);且治疗后两组活动指数评分均明显降低,观察组降低至(2.4±1.6)分,对照组为(5.1±1.5)分,观察组降低幅度明显高于对照组(P<0.05);观察不良反应发生率为5.0%,对照组为12.5%,两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论溃疡性结肠炎患者采用肠道微生态制剂方案可改善临床症状,降低炎症活动度,有较好的临床应用价值。
Objective To observe the effect of intestinal probiotics in patients with ulcerative colitis. Methods Eighty patients with ulcerative colitis admitted to our hospital from March 2013 to March 2015 were selected and divided into control group and observation group according to the random number table method. Each group included 40 patients. The control group received routine treatment. The observation group Treatment of intestinal probiotics. Both groups were treated for 6 months to assess the clinical symptoms of patients to improve the situation, record the incidence of adverse reactions. Results After treatment, the scores of constipation, abdominal pain and abdominal distension in the observation group decreased to (0.8 ± 0.3), (0.6 ± 0.4) and (0.7 ± 0.5) points respectively, with a significant decrease in the observation group, with significant difference between the two groups (P <0.05). After treatment, the index of activity index in both groups decreased significantly (2.4 ± 1.6) in the observation group and (5.1 ± 1.5) in the control group, and the decrease in the observation group was significantly higher than that in the control group <0.05). The incidence of adverse reactions was 5.0% in the control group and 12.5% in the control group. There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusions Patients with ulcerative colitis using gut microecologics can improve clinical symptoms, reduce the degree of inflammatory activity, and have good clinical value.